Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi’s (NASDAQ:SNY) growth is propelled by strong demand for its flagship drugs such as Dupixent (for asthma and eczema) ...

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

Hudson says many CEOs are scared of AI, comparing it to The Terminator’s John Connor traveling back in time to stop the rise ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third ...

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

The 58,000 sq m plant – Sanofi’s second factory in Singapore – will produce vaccines and other biopharmaceutical products ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.